Mersana Therapeutics Overview
- Founded
-
2001
- Status
-
Public
- Employees
-
169
- Stock Symbol
-
MRSN
- Share Price
-
$7.45
- (As of Thursday Closing)
Mersana Therapeutics General Information
Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Contact Information
Website
www.mersana.com
Formerly Known As
Nanopharma, Nanopharma Corporation
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 840 Memorial Drive
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
Mersana Therapeutics Timeline
Mersana Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.45 | $7.82 | $2.68 - $14.80 | $760M | 97.2M | 1.53M | -$2.44 |
Mersana Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 255,716 | 274,803 | 1,568,610 | 155,855 |
| Revenue | 6,342 | 43 | 828 | 42,123 |
| EBITDA | (190,866) | (168,003) | (87,100) | (28,955) |
| Net Income | (193,931) | (170,060) | (88,045) | (28,208) |
| Total Assets | 252,351 | 206,111 | 273,399 | 107,541 |
| Total Debt | 37,427 | 38,176 | 16,572 | 7,764 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Mersana Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mersana Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Mersana Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC plat
Biotechnology
Cambridge, MA
169
As of 2021
00000
000000000
00000
000000
rem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
0000000000000
Beijing, China
000
As of 0000
00000
0000000 0000
00000
000000
a aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea c
0000 000000000
Boston, MA
0
As of 0000
00000
000000000
00000
Add Comparison
Mersana Therapeutics Competitors (62)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mabworks Biotech | Private Equity-Backed | Beijing, China | 000 | 00000 | 0000000 0000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Boston, MA | 0 | 00000 | 000000000 | 00000 |
| 00000000 | Private Equity-Backed | San Carlos, CA | 00 | 00000 | 000000000 | 00000 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
Mersana Therapeutics Patents
Mersana Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210220477-A1 | Site specific antibody-drug conjugates with peptide-containing linkers | Pending | 09-Jan-2020 | 000000000 | |
| US-11155567-B2 | Sting agonist compounds and methods of use | Active | 02-Aug-2019 | 0000000000 | 00 |
| US-20210032269-A1 | Sting agonist compounds and methods of use | Granted | 02-Aug-2019 | 0000000000 | |
| EP-3717021-A1 | Pyrrolobenzodiazepine antibody conjugates | Pending | 27-Nov-2017 | 00000000000 | |
| JP-2020525441-A | Drug-bearing polymer scaffolds and methods of making protein-polymer-drug conjugates | Pending | 22-Jun-2017 | A61K38/08 |
Mersana Therapeutics Executive Team (23)
Mersana Therapeutics Board Members (20)
| Name | Representing | Role | Since |
|---|---|---|---|
| Allene Diaz | Mersana Therapeutics | Board Member | 000 0000 |
| Andrew Hack Ph.D | Self | Board Member | 000 0000 |
| Anna Protopapas | Mersana Therapeutics | Chief Executive Officer, President & Board Member | 000 0000 |
| David Mott | Self | Chairman | 000 0000 |
| Kristen Hege MD | Self | Board Member | 000 0000 |
Mersana Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Mersana Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|